For many forms of childhood cancer, we’ve seen little to no advancement in treatment options for over 30 years.
There are new discoveries made in research labs, but sadly they are rarely if ever translated into new treatments for children. The process of turning a new scientific discovery into a new treatment is tedious, time-consuming, and rarely generates big profits. Kids wait for cures in hospital beds while potential discoveries lie dormant in scientific journals. Today we still have childhood cancers without any effective treatments upon diagnosis or relapse.
One in every 5 children has one of these incurable cancers that even 40 years of ongoing research doesn’t address. To overcome this stalemate, cc-TDI is embarking upon a bold scientific course of discovery to send more targeted drugs into clinical trials for those childhood cancers that have the most dire outcomes.
Our research team is exploring and testing state-of-the-art treatment options for the most urgent issues facing children with cancer.
Biologists and bio-medical engineers work closely on teams to identify targets on cancer cells and determine how to safely deliver effective treatments. By proving these methods in the laboratory, we can deliver smart, hope-filled discoveries to be prioritized in clinical trials for kids.
Working in our own freestanding research institution allows us to act swiftly and nimbly to achieve results—bringing cost control, speed, purpose, and focus to translate effective treatments into the clinic. To get there, we perform basic science and translational research in our industrial modern lab site (a paint factory remodeled by Nike as an off-site creative space), adjacent to the Silicon Forest in Oregon.
Our mission is to translate scientific discovery into clinical trials by understanding and proving new disease-specific treatment options for children with cancer.
This concept was emphasized in the Institute of Medicine Report, Making Better Drugs for Children with Cancer in 2005. cc-TDI now fills this crucially needed role created as a result of the ever-changing climate of federal funding for childhood cancer research.
We believe that patients, their families, and the community are our partners in research, and that shared information will lead to the accelerated development of more effective drugs for childhood cancer.